Skip to content

Robotic Assisted Transanal Total Mesorectal Excision Surgery for Rectal Cancer in Low Site

A Prospective Cohort Study of Robotic Transanal Total Mesentery Excision Versus Conventional Robotic Surgery for Rectal Cancer in Low Site

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03422835
Enrollment
50
Registered
2018-02-06
Start date
2018-02-15
Completion date
2023-12-30
Last updated
2018-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectal Neoplasms

Keywords

transanal surgery, robotic surgery, total mesorectal excision

Brief summary

To investigates the feasibility, practicability, safety and subjective as well as functional outcome of Robotic transanal total mesentery excision for rectal cancer in low site.

Detailed description

Transanal total mesorectal excision (TaTME) may offer a better way to achieve radical resection and functional protection for lower rectal cancer, which have been regarded as challenging situations in rectal cancer surgery. However, the narrow angle and limited space of the operation restrict the wide spread of this technique. Da Vinci robotic system has achieved good results in rectal cancer surgery. Robotics may help to overcome technical difficulties in TaTME. The purpose of this study was to explore the availability of Da Vinci robotic-assisted transanal total mesorectal excision(R-TaTME) This study investigates the feasibility, practicability, safety and subjective as well as functional outcome of Robotic transanal total mesentery excision for rectal cancer in low site.

Interventions

PROCEDURER-TME

Conventional Robotic Total Mesentery Excision

PROCEDURER-TaTME

Robotic Transanal Total Mesentery Excision

Sponsors

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* adenocarcinoma of the rectum by biopsy * the lower edge of the tumor from the anal margin less than 8cm according to MRI or rigid endoscopy * tumor diameter less than 4cm * baseline clinical stage I-III: cT1-3 N0-2 M0 (AJCC v7) * tolerable to surgery * be able to understand and willing to participate in this trial with signature

Exclusion criteria

* history of malignant colorectal neoplasia * recent diagnosis with other malignancies * patients requiring emergency surgery such as obstruction,perforation and bleeding * tumor involving adjacent organs, anal sphincter, or levator ani muscle muti-focal colorectal cancer * preoperative poor anal function, anal stenosis, anal injury, or fecal incontinence history of inflammatory bowel disease or familial adenomatous polyposis * participating in other clinical trails * History of pelvic radiation * BMI \> 40 * Large uterine fibroids * can not tolerate the surgery * history of serious mental illness * pregnancy or lactating women * preoperative uncontrolled infection * the researchers believe the patients should not enrolled in

Design outcomes

Primary

MeasureTime frameDescription
Positive rate of circumferential resection margin (CRM) of the specimens10 days after surgeryCircumferential resection margin (CRM) is the distance between the deepest point of tumor in the primary cancer and the margin of resection in the retroperitoneum or mesentery by pathological examination. CRM 0-1mm is defined as positive, while \>1mm is negative.

Secondary

MeasureTime frameDescription
postoperative hospital stay3 years after surgeryrecovery information.
disease free survival rate3 years after surgerythe oncological efficacy by 3-year follow-up according to the NCCN guideline. Participants should report every follow-up examinations which prove tumor recurrence and/or metastasis or not.
overall survival rate3 years after surgerythe oncological efficacy by 3-year follow-up according to the NCCN guideline. Participants should report every follow-up examinations which prove tumor recurrence and/or metastasis or not.
the rate of postoperative complications30 days after surgerypreoperative safety containing operation information, complication information.
The grade score of the specimens integrity10 days after surgerythe quality of the specimens: grade 1 is bad gross specimen which means incomplete mesorectum and pelvic fascia, and muscle layer can be see \>5mm; grade 3 is high quality gross specimen, which means the specimen is cylindrical, mesorectum and pelvic fascia are complete; grade 2 is between 1and 3.
The distance between lower tumor margin and the lower reaction margin10 days after surgerythe oncological safety of the surgery by pathological examination. Reports should contain the distance between lower tumor margin and the lower reaction margin.

Other

MeasureTime frameDescription
Quality of life outcomes evaluation2 years rafter surgeryWe examine before operation, 3 months after, 6 months after, 12 months after, 24 months after operation, by questionnaires (Short Form-36 (SF36).
defecating functional outcomes3 years after surgeryWexner scale
sexual functional outcomes2 years after surgeryWe examine before operation, 3 months after, 6 months after, 12 months after, 24 months after operation, by questionnaires (International Index of Erectile Function (IIEF)

Contacts

Primary Contactfan li, MD.
levinecq@163.com+86 023 68757958

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026